What is molecularly targeted therapy for tumors

First, targeted drugs for cancer** are often indicated for patients who cannot undergo surgery in advanced cancer. Patients can then survive for years after the use of targeted drugs. This cannot be generalized as there are many influencing factors, which are determined based on the individual situation of the patient.

For example, in patients with advanced small cell lung cancer, the survival period is about 8-10 months without targeted drugs**. If targeted drugs** are used, patients can survive for about 2-5 years.

Targeting ** is a new method, and we now find that tumors have certain targets and certain blood routes. Tumor is also a kind of cell produced in the normal body, and it also depends on our blood to bring nutrients to it, and now it is only found that the endothelial cells in the blood vessels in the blood supply of the tumor can be inhibited by certain drugs. As long as this drug is ingested, the loss to the body is actually relatively low, and it can inhibit the production of blood vessels in the tumor and allow the tumor to naturally apoptosis.

It is equivalent to starving the tumor to death. But the discovery of this targeted drug. Not it works for all cancer patients.

It is only for certain specific patients. Therefore, we also need to do certain testing work to determine whether the drug is effective for you before doing tumor**. Probably less than 30% of people in Asia can apply it**.

Minor cancers.

Extended information: Targeting is a way to target a well-defined oncogenic site at the cellular molecular level (which can be a protein molecule inside a tumor cell or a gene fragment).

The corresponding ** drug can be designed, and the drug will specifically select the carcinogenic site to combine and act when it enters the body, so that the tumor cells will die specifically, and will not affect the normal tissue cells around the tumor, so molecular targeting** is also known as "biological missile".

In addition to conventional surgery, radiotherapy, chemotherapy, biology and traditional Chinese medicine, different targeting technologies can be used to target tumors at the organ, tissue, and molecular levels. Local lesion targets can be targeted by local targeted ablation**, targeted radiation**, targeted internal irradiation with radioactive seed implantation**, high-energy focused ultrasound**, endovascular intervention**, and local drug injection**. The target of molecular targeting** is a malignant phenotypic molecule targeting tumor cells, acting on specific cell receptors, signaling and other channels that promote tumor growth and survival, regulating neovascularization and cell cycle, and achieving anti-tumor effects that inhibit tumor cell growth or promote apoptosis.

Different from traditional cytotoxic chemotherapy, tumor molecular targeting** has specific anti-tumor effects and significantly reduced toxicity, opening up a new field of tumor chemotherapy.

With the development of society and science and technology, the concept of cancer is undergoing fundamental changes, that is, from empirical science to evidence-based medicine, from cell attack mode to targeted ** model. The "targeting**" of precise drug delivery to the tumor region using targeted technology and the "target**" using tumor-specific signaling or specific metabolic pathway control are the hotspots of tumor research.

According to the different target sites, tumor targeting** can be divided into two categories, namely tumor cell targeting** and tumor vascular targeting**. Tumor cell targeting** uses specific antigens or receptors on the surface of tumor cells as targets, while tumor vascular targeting** uses specific antigens or receptors on the surface of neovascular endothelial cells in the tumor region. Although the targeting properties of those monoclonal antibodies against tumor cells increase the concentration within the local tumor tissue to some extent, the process is relatively slow because these macromolecules still need to pass through the vascular endothelial cell barrier to reach the tumor cell target.

Vascular-targeted drugs, on the other hand, have the advantage of accumulating rapidly and in high concentrations at the target site after administration.